The ABHD6 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population generated from HT29 colorectal adenocarcinoma cells for loss-of-function analysis of ABHD6. This product consists of a heterogeneous pool of cells with ABHD6 gene disruptions, avoiding clonal bias while preserving editing diversity. ABHD6 encodes a monoacylglycerol lipase that hydrolyzes 2-arachidonoylglycerol (2-AG), a key endocannabinoid; its knockout is expected to profoundly alter lipid signaling networks in these cancer cells.
HT29 human colorectal adenocarcinoma epithelial cells harbor a mutant p53 background, form polarized monolayers, and can differentiate into mucus-secreting cells. As a colorectal cancer model, they feature aberrant Wnt/??-catenin signaling and are suitable for studying lipid metabolism and endocannabinoid pathways in intestinal epithelium.
ABHD6 functions as a principal monoacylglycerol lipase that hydrolyzes 2-arachidonoylglycerol (2-AG), terminating endocannabinoid tone at CB1 and CB2 receptors while liberating arachidonic acid for pro-inflammatory eicosanoid synthesis via COX-2 and LOX. Its activity is modulated by upstream signals including PPAR??, insulin, EGF, and TNF-??, and it impinges on downstream effectors such as ERK1/2, AKT, mTOR, and ??-catenin. In the knockout state, elevated 2-AG levels enhance cannabinoid receptor activation, driving MAPK/ERK and PI3K/AKT pathway signaling and influencing Wnt/??-catenin transcriptional programs. This disruption also alters prostaglandin E2 production and lipid droplet dynamics, rewiring the broader lipid signaling network and intersecting with key oncogenic cascades.
In HT29 colorectal cancer cells, ABHD6 knockout provides a robust model to dissect the role of endocannabinoid-mediated control of oncogenic signaling. The anticipated rise in 2-AG enhances CB1/CB2-mediated modulation of proliferation, apoptosis, and migration, potentially revealing both tumor-suppressive and tumor-promoting functions. This system is particularly apt for studying how lipid metabolic rewiring intersects with ??-catenin-driven transcription and AKT-mTOR survival pathways, and for exploring links to inflammatory bowel disease given the intestinal origin of the cells.
Researchers can employ these polyclonal knockout cells to investigate endocannabinoid signaling in colorectal cancer, screen ABHD6 inhibitors, and assess the impact of elevated 2-AG on cell proliferation, apoptosis, and migration. Compatible assays include Western blotting for ABHD6, CB1, CB2, phospho-ERK, phospho-AKT, and ??-catenin; RT-qPCR for downstream targets such as EGR1 and c-MYC; and LC-MS/MS for quantitative profiling of 2-AG and eicosanoids. Functional studies can be performed using MTT/BrdU proliferation assays, Annexin V/PI apoptosis detection, and Transwell migration/invasion systems. Pharmacological treatments with CB1/CB2 agonists or antagonists enable pathway interrogation, while dual-luciferase reporters measure Wnt/TCF activity. For additional technical information, please contact Ascent Research.
